Iris Grossman, PhD

Iris Grossman, PhD is an experienced professional with a diverse background in the biotechnology and pharmaceutical industries. Iris currently holds the position of Chief Therapeutics Officer at Eleven Therapeutics, where they are responsible for overseeing therapeutic strategies. Prior to this, they served as the Chief Strategy Officer and a Scientific Advisory Board (SAB) member at Eleven Therapeutics.

In addition to their role at Eleven Therapeutics, Iris is a Strategic Founder Advisor at Modulight.bio, a company focused on developing transformative medicines for neurological disorders. Iris joined Modulight.bio in 2022.

Before joining Eleven Therapeutics and Modulight.bio, Iris worked at BC Platforms as an SAB member. BC Platforms specializes in genomic data management and analysis solutions for the healthcare industry.

In 2007, Iris co-founded and served as the President of GROSS Advantage (formerly IsraGene), a therapeutic strategy consultancy. GROSS Advantage offers services in human genetics, pharmacogenomics, biomarkers, and digital-markers to support drug and diagnostic R&D.

Iris has also held positions at Amide Technologies as the Chief Scientific Officer (acting), CAMP4 Therapeutics as the Chief Scientific Officer, Teva Pharmaceuticals in various leadership roles, Zinfandel Pharmaceuticals as a Member of the Board of Advisors, Cabernet Pharmaceuticals as the Director of Pharmacogenetics Consultancy, and GlaxoSmithKline as a Pharmacogenetics Manager.

Throughout their career, Iris has demonstrated expertise in areas such as personalized medicine, pharmacogenomics, drug development, and strategic planning. Iris is dedicated to driving innovation in the field of healthcare and contributing to the development of new therapies and treatments to improve patient outcomes.

Iris Grossman, PhD's education history includes a Bachelor of Science (B.Sc.) degree and a Direct PhD in Medicine/Pharmacogenetics from the Technion - Israel Institute of Technology. Iris pursued their PhD in collaboration with co-mentors at the Weizmann Institute of Science, focusing on Pharmacogenetics and population genetics. In 2018, they participated in the Executive HealthTech Program at the Harvard Business School.